ArticleMolecular biology reports2025
Effects of empagliflozin on interleukin-23 secretion from peripheral blood mononuclear cells in patients with type 2 diabetes versus healthy subjects: an in vitro study.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesChronic inflammation is a critical contributor to the pathogenesis of type 2 diabetes mellitus (T2DM). Interleukin-23 (IL-23) is recognized as a key pro-inflammatory cytokine involved in immune dysregulation. Empagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, has been shown to exert anti-inflammatory effects; however, its specific influence on IL-23 production in peripheral blood mononuclear cells (PBMCs) remains unclear. This study aims to evaluate the impact of empagliflozin on IL-23 secretion in PBMCs isolated under in vitro conditions.
methodsThis in vitro case-control study was conducted in Iran in 2024 and included 50 participants (23 males and 27 females), comprising 25 individuals with T2DM and 25 age- and sex-matched healthy controls. Blood samples were collected from all participants to assess fasting blood glucose (FBG) and hemoglobin A1c (HbA1c) levels. In vitro, empagliflozin was added to the blood samples at a concentration of 100 µg/mL. IL-23 levels were measured in both groups before and after treatment with empagliflozin. Statistical analyses were conducted using SPSS version 21.
resultsStatistical analysis revealed that IL-23 secretion from PBMCs cultured with empagliflozin was significantly reduced compared to untreated cultures in both individuals with T2DM (p < 0.001) and healthy controls (p = 0.048). Baseline IL-23 levels were significantly higher in the T2DM group compared to the control group, and this difference remained significant following empagliflozin treatment (p = 0.021). Moreover, the magnitude of empagliflozin's effect on IL-23 secretion differed significantly between the two groups (p = 0.016). In the T2DM group, IL-23 secretion showed a positive correlation with FBG and HbA1c levels in the absence of empagliflozin; however, these correlations were weak or non-significant following treatment. No significant correlations were observed in the control group under either condition.
conclusionEmpagliflozin significantly reduces IL-23 secretion in both T2DM patients and healthy individuals, with a more pronounced effect observed in those with T2DM. These findings suggest that empagliflozin may exert anti-inflammatory effects independent of glycemic control, underscoring its potential role in mitigating immune dysregulation and chronic inflammation in T2DM.
Indexed as
Identifiers
40719934What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.